Gadopiclenol, also known as gadopentetate dimeglumine, is a type of contrast agent used in magnetic resonance imaging (MRI) and computed tomography (CT) scans. It is a gadolinium-based contrast agent that is injected into the bloodstream to enhance the visibility of certain areas in the body during MRI or CT scans. It typically allows the radiologist to better identify soft tissue, organs and blood vessels. Gadopiclenol is typically used to diagnose and monitor a variety of diseases and conditions, including tumors, stroke, heart disease, liver and kidney disorders, and infections.
Gadopiclenol is a contrast agent used with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and in the body. It is sold under brand names such as Elucirem and Vueway .
Gadopiclenol is a type of gadolinium-based contrast agent (GBCA). GBCAs are a class of drugs that are injected into a patient's vein before an MRI scan. They help to improve the visibility of certain tissues and organs on the MRI scan.
Gadopiclenol works by shortening the relaxation time of water molecules in the body. This makes it easier for the MRI scanner to detect these water molecules and create a detailed image.
Gadopiclenol has a higher relaxivity compared with standard gadolinium-based contrast agents (GBCAs). The higher relaxivity allows for a lower dose of gadopiclenol, reducing the total amount of gadolinium administered to the patient while preserving imaging quality. Gadopiclenol was approved by the FDA with a recommended dose of 0.05 mmol/kg for adults and pediatric patients aged 2 years and older. This is half the dose of standard macrocyclic GBCAs, which have a recommended dose of 0.1 mmol/kg.